Genetic and Clinical Study of Patients With Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy



Status:Archived
Conditions:Skin Cancer, Cancer, Cancer, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011

Use our guide to learn which trials are right for you!

Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy


RATIONALE: Genetic studies may help in understanding the genetic processes involved in the
development of some types of cancer and may lead to both earlier detection and prevention of
tumors.

PURPOSE: Clinical trial to study the genetic and clinical features of patients who have
xeroderma pigmentosum, Cockayne syndrome, the xeroderma pigmentosum/Cockayne syndrome
complex, or trichothiodystrophy.


OBJECTIVES:

- Identify patients or confirm suspected cases of xeroderma pigmentosum (XP), Cockayne
syndrome (CS), XP/CS, or trichothiodystrophy (TTD).

- Document presence or absence of cancers (skin, eye, tongue, or internal) in these
patients.

- Document atypical features or unusual environmental exposures of these patients.

- Examine tissue (skin, blood, hair, or buccal swabs) from these patients and their first
degree relatives for DNA repair and genetic analysis.

- Identify molecular defects in the DNA repair genes in cells from these patients and
correlate the defects with clinical features.

- Follow the clinical course of selected patients.

OUTLINE: Patients are evaluated initially by phone, followed by a complete history and
physical exam, including appropriate clinical and laboratory tests.

Tissue (skin, blood, buccal swabs, or hair) is obtained for laboratory studies of the
effects of DNA damage, measurement of DNA repair, genetic analysis of DNA, and/or assessment
of immunologic abnormalities.

If malignancies are detected during examinations and tissue collections, patients are
referred for treatment. Genetic counseling is also available.

Patients are followed annually.

PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.


We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
1-800-422-6237
National Cancer Institute (NCI) The National Cancer Institute (NCI) is part of the National Institutes...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials